2026

Janha, Omar, Olaniyan, Niniola, Diam, Go Ka, Sharma, Saumya, Beraldi, Dario, Jamieson, Andrew G. ORCID: https://orcid.org/0000-0003-1726-7353, Bozdech, Zbynek, Tobin, Andrew B. ORCID: https://orcid.org/0000-0002-1807-3123 and Modrzynska, Katarzyna ORCID: https://orcid.org/0000-0002-0877-3564 (2026) Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates. Antimicrobial Agents and Chemotherapy, (doi: 10.1128/aac.01561-25) (Early Online Publication)

2024

Brettell, S. B. et al. (2024) Targeting PfCLK3 with covalent inhibitors: a novel strategy for malaria treatment. Journal of Medicinal Chemistry, 67(21), pp. 18895-18910. (doi: 10.1021/acs.jmedchem.4c01300) (PMID:39441986) (PMCID:PMC11571108)

2021

Mahindra, A. et al. (2021) Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 16(11), e0260283. (doi: 10.1371/journal.pone.0260283) (PMID:34793553) (PMCID:PMC8601423)

2020

Mahindra, Amit, Janha, Omar, Mapesa, Kopano, Sanchez Azqueta, Ana, Alam, Mahmood M. ORCID: https://orcid.org/0000-0003-2148-4887, Amambua-Ngwa, Alfred, Nwakanma, Davis C., Tobin, Andrew B. ORCID: https://orcid.org/0000-0002-1807-3123 and Jamieson, Andrew G. ORCID: https://orcid.org/0000-0003-1726-7353 (2020) Development of potent PfCLK3 inhibitors based on TCMDC-135051 as a new class of antimalarials. Journal of Medicinal Chemistry, 63(17), pp. 9300-9315. (doi: 10.1021/acs.jmedchem.0c00451) (PMID:32787140) (PMCID:PMC7497403)

2019

Alam, M. M. et al. (2019) Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Science, 365(6456), eaau1682. (doi: 10.1126/science.aau1682) (PMID:31467193)

Articles

Janha, Omar, Olaniyan, Niniola, Diam, Go Ka, Sharma, Saumya, Beraldi, Dario, Jamieson, Andrew G. ORCID: https://orcid.org/0000-0003-1726-7353, Bozdech, Zbynek, Tobin, Andrew B. ORCID: https://orcid.org/0000-0002-1807-3123 and Modrzynska, Katarzyna ORCID: https://orcid.org/0000-0002-0877-3564 (2026) Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates. Antimicrobial Agents and Chemotherapy, (doi: 10.1128/aac.01561-25) (Early Online Publication)

Brettell, S. B. et al. (2024) Targeting PfCLK3 with covalent inhibitors: a novel strategy for malaria treatment. Journal of Medicinal Chemistry, 67(21), pp. 18895-18910. (doi: 10.1021/acs.jmedchem.4c01300) (PMID:39441986) (PMCID:PMC11571108)

Mahindra, A. et al. (2021) Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 16(11), e0260283. (doi: 10.1371/journal.pone.0260283) (PMID:34793553) (PMCID:PMC8601423)

Mahindra, Amit, Janha, Omar, Mapesa, Kopano, Sanchez Azqueta, Ana, Alam, Mahmood M. ORCID: https://orcid.org/0000-0003-2148-4887, Amambua-Ngwa, Alfred, Nwakanma, Davis C., Tobin, Andrew B. ORCID: https://orcid.org/0000-0002-1807-3123 and Jamieson, Andrew G. ORCID: https://orcid.org/0000-0003-1726-7353 (2020) Development of potent PfCLK3 inhibitors based on TCMDC-135051 as a new class of antimalarials. Journal of Medicinal Chemistry, 63(17), pp. 9300-9315. (doi: 10.1021/acs.jmedchem.0c00451) (PMID:32787140) (PMCID:PMC7497403)

Alam, M. M. et al. (2019) Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Science, 365(6456), eaau1682. (doi: 10.1126/science.aau1682) (PMID:31467193)